Consensus The Chemours Company

Equities

CC

US1638511089

Market Closed - Nyse 04:00:05 2024-07-12 pm EDT 5-day change 1st Jan Change
24.5 USD +0.99% Intraday chart for The Chemours Company +10.81% -22.32%

Evolution of the average Target Price on The Chemours Company

Price target over the last 5 years

History of analyst recommendation changes

651.Ik899ZUpUXvZWOK89bWbT-q3Dy3T1anuK5nZxi8s61Y.Yx1Tt7htCTavaorFzN7THLXOPHeDp_PdTK2av318uDVvPHu7xx9kH5VhgQ~a37c5415521f7585251dae1a2fd69407
UBS Upgrades Chemours to Buy From Neutral, Raises Price Target to $30 From $28 MT
Mizuho Initiates Chemours With Neutral Rating, $25 Price Target MT
Hudson Technologies Signs Licensing Agreement With Chemours MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline MT
BMO Capital Upgrades Chemours to Outperform From Underperform, Raises Price Target to $34 From $19 MT
UBS Adjusts Chemours Price Target to $28 From $21, Maintains Neutral Rating MT
UBS Downgrades Chemours to Neutral From Buy, Cuts Price Target to $21 From $37 MT
BMO Capital Downgrades Chemours to Underperform From Outperform, Adjusts Price Target to $19 From $45 MT
RBC Upgrades Chemours to Outperform From Sector Perform, Lifts Price Target to $40 From $28 on Titanium Technologies Recovery, Thermal & Specialized Solutions Strength MT
Goldman Sachs Adjusts Chemours' Price Target to $30 From $35, Maintains Neutral Rating MT
BMO Capital Adjusts Chemours' PT to $39 From $45, Keeps Outperform Rating MT
Morgan Stanley Cuts Price Target on Chemours to $28 From $33, Maintains Equal-Weight Rating MT
Barclays Cuts Price Target on Chemours to $28 From $31, Maintains Equal-Weight Rating MT
RBC Cuts Price Target on Chemours to $28 From $30, Keeps Sector Perform Rating MT
UBS Cuts Chemours Price Target to $37 From $41, Maintains Buy Rating MT
RBC Cuts Price Target on Chemours to $30 From $40, Keeps Sector Perform Rating MT
BofA Securities Adjusts Price Target on Chemours to $32 From $39, Maintains Neutral Rating MT
UBS Cuts Chemours Price Target to $41 From $47, Maintains Buy Rating MT
Barclays Adjusts Price Target on Chemours to $31 From $40, Keeps Equalweight Rating MT
BMO Capital Adjusts Price Target on Chemours to $53 From $64, Maintains Outperform Rating MT
RBC Boosts Price Target on Chemours to $40 From $37, Maintains Sector Perform Rating MT
UBS Adjusts Chemours Price Target to $47 From $43, Maintains Buy Rating MT
Barclays Adjusts Price Target on Chemours Company to $40 From $38, Maintains Equalweight Rating MT
BofA Securities Downgrades Chemours to Neutral From Buy, Lowers Price Target to $37 From $41 MT
UBS Raises Chemours' Price Target to $43 From $41, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
24.51 USD
Average target price
29.9 USD
Spread / Average Target
+21.99%
High Price Target
35 USD
Spread / Highest target
+42.80%
Low Price Target
25 USD
Spread / Lowest Target
+2.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering The Chemours Company

Mizuho Securities
BMO Capital
UBS
RBC Capital Markets
Goldman Sachs
Morgan Stanley
Barclays
BofA Securities
JPMorgan Chase
Credit Suisse
Citigroup
Argus
Alembic Global
Wolfe Research
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. CC Stock
  4. Consensus The Chemours Company